Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) EBIT: 2022-2025

Historic EBIT for InMed Pharmaceuticals (INM) over the last 4 years, with Jun 2025 value amounting to -$7.9 million.

  • InMed Pharmaceuticals' EBIT fell 4.94% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.0 million, marking a year-over-year decrease of 10.66%. This contributed to the annual value of -$7.9 million for FY2025, which is 3.05% up from last year.
  • As of FY2025, InMed Pharmaceuticals' EBIT stood at -$7.9 million, which was up 3.05% from -$8.2 million recorded in FY2024.
  • In the past 5 years, InMed Pharmaceuticals' EBIT registered a high of -$7.9 million during FY2025, and its lowest value of -$17.3 million during FY2022.
  • For the 3-year period, InMed Pharmaceuticals' EBIT averaged around -$8.2 million, with its median value being -$8.2 million (2024).
  • Data for InMed Pharmaceuticals' EBIT shows a peak YoY spiked of 51.19% (in 2023) over the last 5 years.
  • InMed Pharmaceuticals' EBIT (Yearly) stood at -$17.3 million in 2022, then spiked by 51.19% to -$8.4 million in 2023, then grew by 2.74% to -$8.2 million in 2024, then rose by 3.05% to -$7.9 million in 2025.